Novartis Teams With Pear Therapeutics In Neurological Digital Health Pact

Duo aims to get Pear's THRIVE digital therapeutic approved, and to develop a new application to treat MS patients, then seek validation in clinical studies.

Digital screen
Duo Will Develop Clinically-Validated Software Used for Schizophrenia and MS • Source: Shutterstock

Signalling its intent to embrace emerging digital technologies in the realm of neuro-degenerative and psychiatric diseases, Novartis AG has joined Pear Therapeutics in a collaboration on prescription software applications aimed at treating patients with schizophrenia and multiple sclerosis.Prescription digital therapeutics are clinically validated, FDA-cleared software applications that show safety and efficacy in randomized clinical trials to improve patient outcomes.

"We see digital therapeutics as a potentially vital part of future treatment models across a range of diseases with high unmet medical need - offering patients pharmacological drug treatments prescribed along-side proven digital therapeutics

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Drug Pricing

More from Scrip